Phase 2 Non-Alcoholic Fatty Liver Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing to give their written agreement to take part after being fully informed about what the trial involves, including possible side effects.
- People who are between 18 and 65 years old (including those exact ages).
- People whose liver fat level is measured at 10% or higher at the screening stage.
- Female participants who agree not to donate eggs from the start of the screening period until at least 28 days after stopping the study drug; male participants who agree not to donate sperm during the same timeframe.
- People who agree to use effective contraception throughout the study and for 6 months after the last dose of the study drug.
Who may not be able to join:
- People who have a known or suspected allergic reaction (confirm with trial site).
- People who have been diagnosed with cirrhosis of the liver, either through a liver biopsy or a clinical diagnosis.
- People with Type 1 diabetes, or people with Type 2 diabetes that is not well controlled (based on a specific blood sugar marker called HbA1c being 8.0% or above).
- People who have other liver or gallbladder conditions that the trial doctor believes could affect the results or safety of the study.
- People who have a thyroid condition, or whose thyroid function test results show a clinically significant problem.
- People who, within the past year, have had a heart attack, unstable chest pain, heart bypass surgery, stroke, brain bleed, or other serious heart or brain blood vessel events that required a hospital stay.
- People who have had a liver transplant, or who are planning to have one.
- People who have significantly changed their diet or exercise habits in the past 2 months, or whose weight has changed by more than 5% in that time.
- People who have taken certain medications within the past 4 weeks (or longer, depending on the drug) that affect how the liver breaks down substances — specifically drugs that strongly affect a liver enzyme called CYP2C8 (confirm with trial site).
- People who are pregnant or currently breastfeeding.
- People who are unable to have an MRI scan for any reason.
- People the trial doctor considers unsuitable for the study for any other reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86-15810092973
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The relative change in liver fat fraction from the baseline by magnetic resonance proton density fat fraction (MRI-PDFF).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.